NYMC Faculty Publications
DOI
10.1186/s13045-017-0512-1
Journal Title
Journal of Hematology & Oncology
First Page
145
Document Type
Article
Publication Date
7-28-2017
Department
Medicine
Abstract
Spleen tyrosine kinase (Syk) is a cytosolic non-receptor protein tyrosine kinase (PTK) and is mainly expressed in hematopoietic cells. Syk was recognized as a critical element in the B-cell receptor signaling pathway. Syk is also a key component in signal transduction from other immune receptors like Fc receptors and adhesion receptors. Several oral Syk inhibitors including fostamatinib (R788), entospletinib (GS-9973), cerdulatinib (PRT062070), and TAK-659 are being assessed in clinical trials. The second generation compound, entospletinib, showed promising results in clinical trials against B-cell malignancies, mainly chronic lymphoid leukemia. Syk inhibitors are being evaluated in combination regimens in multiple malignancies.
Recommended Citation
Liu, D., & Mamorska-Dyga, A. (2017). Syk Inhibitors in Clinical Development for Hematological Malignancies. Journal of Hematology & Oncology, 10 (1), 145. https://doi.org/10.1186/s13045-017-0512-1
Publisher's Statement
Originally published in Journal of Hematology & Oncology, 10 (1), 145. The original material can be found here.
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Included in
Amino Acids, Peptides, and Proteins Commons, Biochemistry Commons, Enzymes and Coenzymes Commons
